• FirefoxUpgrade to the new Firefox »
  •  Dow Down0.79% Nasdaq Up0.16%

    Sequenom Inc. (SQNM)

    -NasdaqGS
    3.62 Down 0.10(2.69%) Jan 23, 4:00PM EST
    |After Hours : 3.62 0.00 (0.00%) Jan 23, 4:31PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Sequenom Inc.
    3595 John Hopkins Court
    San Diego, CA 92121
    United States - Map
    Phone: 858-202-9000
    Fax: 858-202-9001
    Website: http://www.sequenom.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:570

    Business Summary 

    Sequenom, Inc., a life sciences company, provides genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets in the United States and internationally. It operates through two segments, Sequenom Center for Molecular Medicine and Sequenom Bioscience. The Sequenom Center for Molecular Medicine segment provides molecular based, laboratory developed tests (LDTs) with a focus principally on prenatal diseases and conditions, and ophthalmological diseases and conditions. Its LDTs include MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene RHD LDT, a NIPT to determine the presence or absence of fetal Rhesus D factor; and RetnaGene AMD LDT, a genetic test to predict the risk of a patient with dry or early stage age-related macular degeneration. The Sequenom Bioscience segment provides technology and research use only tools, such as the MassARRAY System platform, chip and reagent consumables, software, and biomarker assay panels for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. Its MassARRAY systems are used in a range of DNA/RNA analysis applications, including SNP, genotyping, detection of mutations, analysis of copy number variants, and other structural genome variations, as well as in quantitative gene expression analysis, quantitative DNA methylation analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. This segment also provides contract research services to clinical research laboratories, bioagriculture, biotechnology and pharmaceutical companies, academic institutions, and government agencies. The company was founded in 1994 and is headquartered in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Sequenom Inc.

    Corporate Governance 
    Sequenom Inc.’s ISS Governance QuickScore as of Jan 1, 2015 is 10. The pillar scores are Audit: 10; Board: 4; Shareholder Rights: 10; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. William J. Welch M.B.A., 53
    Chief Exec. Officer, Pres and Director
    401.00K0.00
    Dr. Dirk van den Boom Ph.D., 44
    Chief Scientific and Strategy Officer
    376.00K0.00
    Mr. Paul V. Maier M.B.A., 67
    Consultant
    359.00K0.00
    Ms. Carolyn D. Beaver CPA, 57
    Chief Financial Officer, Chief Accounting Officer and VP
    N/AN/A
    Ms. Marcy Graham ,
    Sr. Director of Investor Relations & Corp. Commmunications
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders